||EPS - Basic
||Market Cap (m)
|Electronic & Electrical Equipment
Scientific Digital Imaging Share Discussion Threads
Showing 626 to 647 of 650 messages
|RNS - the shareholder list here gets even more ridiculously heavyweight, with Oryx buying almost another 3.9m shares and increasing to 8.35m, or 9.4%:
"Tuesday 17th January 2017
Produlab Pharma uses ProcScan and SynStats to rapidly generate accurate, traceable data on antibiotic potency
Cambridge, UK: Synbiosis, a long-established, expert manufacturer of automated microbiological systems, ispleased to announce its ProcScan inhibition zone measurement system is being used together with its SynStats statistical analysis software at specialist Dutch veterinary pharmaceutical firm, Produlab Pharma to accurately and reproducibly assess the quality of veterinary antibiotics.
Microbiologists at Produlab Pharma are using the ProcScan automated system to generate images of inhibition zones around antibiotics on large (240 mm x 240 mm) antibiotic susceptibility testing plates. The images are scanned directly into software, which automatically measures zone sizes and these values are transferred into SynStats statistical software. This rapidly analyses the results to provide standard curve and potency data. Using ProcScan in combination with SynStats is helping microbiologists at Produlab Pharma to precisely assess the efficacy of existing and re-engineered antibiotics to treat diseases such as mastitis in cattle.
Dave van Reusel, Microbiologist at Produlab Pharma commented: “We used to measure inhibition zones manually with callipers and then record the results on the computer. It would take us 30 minutes to analyse one plate and after this we had no image of our plates to refer to so there was no proof of our results to look at later.”
Dave added: “We chose the ProcScan because it is the only system that can image large antibiotic susceptibility testing plates and measure inhibition zones in a 6 x 6 grid. Before we had the ProcScan, it would require hours to analyse a run of 20-30 assay plates, now it takes a fraction of the time and we can record raw plate images to provide evidence for clients or regulators to assess when they need to.”
“Data integrity is currently a hot issue across the pharmaceutical industry,” stated Kate George, Senior Divisional Manager at Synbiosis, “scientists at Produlab Pharma are demonstrating that ProcScan and SynStats is a must have combination for quality assurance laboratories where generating accurate, consistent and more importantly, archived raw and analysed data of any antibiotics’ potency are critical requirements.”|
"Thursday 12th January 2017
New GeneSys image capture software now available to download
Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to announce its GeneSys software has been upgraded to include an icon of pre-set optimised “stain-free” protein gel imaging conditions. This simple to use software, available to download free of charge to existing users of specified Syngene imaging systems, will save set-up time and ensure accurate stain-free protein gel images every time.....
|Greyingsurfer, hastings and noble3r are correct - notice that the Fund's shareholding has increased by 1.15m shares, it's simply that the placing has diluted their overall interest.
SDI is very volatile and illiquid due to its huge ownership of shares by blue chip institutions, and the MMs adjust the price accordingly. Only £6k has been traded today!|
|The previous dips in July, November and December proved excellent add points|
|Looking very weak now ?|
|Greyingsurfer, number of shares prior to triggering transaction - 7706430, resulting situation after trigger 8860277. This is clearly an increase / purchase of shares but still a tiny dilution after placing.|
|OK, makes sense thanks|
|Greyingsurfer, I'm pretty sure they picked up more in the placing, but overall holding has been reduced through dilution.Business Growth Fund picked the larger chunks up as did Harwood Capital I believe.|
|Are you sure? The RNS says they've reduced from over 12 to under 10%|
|RNS - Octopus Investments have increased their holding by just over 1.15m shares. They now hold 8.86m shares, or 9.97%:
|Oh ok, I could not find it on their web-site or in an RNS but that sounds pretty definitive.
|I have a visit planned to coincide with the interims for a write up, so unless that date is changed between now and then, it should happen on that Tuesday.Hope that helps.H.|
What is the source for 24-Jan please?|
|Interims due on 24th.|
|Correct rivaldo, I believe Harwood Capital, Herald and Miton also added in the placing.|
|Today's RNS is clear that the Business Growth Fund have bought 12% of SDI, or 10.77m shares.
The Fund will have picked up almost half of the placing shares as they weren't a major shareholder before.
Quite a vote of confidence in this still micro-cap company. And it makes the shareholder list even more blue chip than it already was :o))|
|basem1 - Form not correctly filled out - Suggest you phone|
|It's a new holding from the placing.Business Growth Fund from my understanding had been keen to come on board for a while, so I would hope that it will look to add in due course.|
|18.49 to buy, just done a dummy trade. I'll wait it out, seems like a bit of downward pressure at present.|
|-7.5%, 19p to buy no excuses now!|